Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/...
This medicine was designated as an orphan medicine for treatment of mesothelioma on 21 March 2024. This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a …